文献速递妇科肿瘤

围手术期β受体阻滞剂供应与有心血管疾病史的上皮性卵巢癌女性生存

Perioperative Beta-Blocker Supply and Survival in Women With Epithelial Ovarian Cancer and a History of Cardiovascular Conditions.
PubMed 文献 · J Clin Oncol · 2022-08-24

基于澳大利亚3844例50岁以上有心血管疾病史的上皮性卵巢癌手术女性,采用逆概率治疗加权和灵活参数生存模型分析。围手术期供应非选择性β受体阻滞剂者2年生存比例为80%(95%CI 68-88),未供应者为69%(95%CI 67-70),生存优势似延伸至术后至少8年;选择性β受体阻滞剂未见关联。

要点

  • 围手术期供应非选择性β受体阻滞剂者2年生存比例为80%(95%CI 68-88),未供应者为69%(95%CI 67-70)。
  • 非选择性β受体阻滞剂的生存优势似延伸至术后至少8年。
  • 围手术期供应选择性β受体阻滞剂与生存未见关联。

核心结论

  • 围手术期供应非选择性β受体阻滞剂似为50岁以上有心血管疾病史的上皮性卵巢癌女性带来生存优势。
  • 需长期临床试验确认这些发现。

研究设计与样本

  • 基于关联行政数据的澳大利亚人群队列,纳入3844例50岁以上有心血管疾病史并接受上皮性卵巢癌手术的女性,随访生存结局。
  • 采用协变量平衡的逆概率治疗加权和允许时变生存效应的灵活参数生存模型,从因果推断角度估计围手术期供应选择性β受体阻滞剂和非选择性β受体阻滞剂的平均治疗效应。

主要发现

  • 围手术期供应选择性β受体阻滞剂者560例(14.5%),供应非选择性β受体阻滞剂者67例(1.7%)。
  • 术后2年生存比例:围手术期供应非选择性β受体阻滞剂者为80%(95%CI 68-88),未供应者为69%(95%CI 67-70)。
  • 非选择性β受体阻滞剂的生存优势似延伸至术后至少8年。
  • 围手术期供应选择性β受体阻滞剂的女性未见关联。

临床怎么用

  • 作者认为围手术期供应非选择性β受体阻滞剂似为50岁以上有心血管疾病史的上皮性卵巢癌女性带来生存优势。
  • 作者指出需长期临床试验确认这些发现。

局限性

  • 需长期临床试验确认这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Surgery for epithelial ovarian cancer (EOC) may activate stress-inflammatory responses that stimulate tumor growth and increase metastatic growth. Animal and in vitro studies have shown that inhibition of the catecholamine-induced inflammatory response via beta-adrenergic receptor blockade has antitumor potential in EOC. However, observational studies have reported mixed results. We assessed whether beta-blocker (BB) use at the time of primary ovarian cancer surgery was associated with improved survival in a large population-based study. MATERIALS AND METHODS: Using linked administrative data, a population-based cohort of 3,844 Australian women age 50 years or older with a history of cardiovascular conditions who underwent surgery for EOC was followed for survival outcomes. The average treatment effect of selective BB (SBB) and nonselective BB (NSBB) supply at the time of surgery on survival was estimated from a causal inference perspective using covariate-balanced inverse probability of treatment weights with flexible parametric survival models that allowed for time-varying survival effects. RESULTS: Around the time of surgery, 560 (14.5%) women were supplied a SBB and 67 (1.7%) were supplied a NSBB. At 2 years postsurgery, the survival proportion was 80% (95% CI, 68 to 88) for women dispensed NSBBs at surgery compared with 69% (95% CI, 67 to 70) for women not supplied NSBBs. The survival advantage appeared to extend to at least 8 years postsurgery. No association was observed for women dispensed a SBB around the time of surgery. CONCLUSION: Perioperative supply of NSBBs appeared to confer a survival advantage for women age over 50 years with a history of cardiovascular conditions. Long-term clinical trials are required to confirm these findings.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Spilsbury K, Tuesley KM, Pearson SA, et al. Perioperative Beta-Blocker Supply and Survival in Women With Epithelial Ovarian Cancer and a History of Cardiovascular Conditions. J Clin Oncol. 2022. PMID: 36001852. doi:10.1200/JCO.22.00097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。